Navigation Links
Thomson Reuters Study Finds Step Therapy Programs May Increase Overall Healthcare Costs for Employers
Date:3/30/2009

ANN ARBOR, Mich., March 30 /PRNewswire/ -- A health insurance protocol intended to promote the use of effective, cheaper medications may create barriers that lead people to receive less of needed medications, according to a Thomson Reuters study. As a result, patients ultimately require more -- and more costly -- medical care.

The protocol, called "step therapy," requires health plan members to try a first-line medication before they can receive coverage for a second-line medication. (Step therapy is not the same as programs which encourage the substitution of a generic medication for the same brand name medication. Step therapy requires certain types of medications within a class of drugs to be used before a second-line medication is tried, unless a physician obtains prior authorization.)

In the study, a group of patients treated for hypertension under a step therapy program filled prescriptions for less anti-hypertensive medication -- by 7.9 percent -- than a comparison group with no step therapy requirement. The step therapy group also had 3.1 percent lower drug costs. (These effects declined in each subsequent quarter.)

As drug utilization declined, hospital admissions and emergency room visits increased. Two years after the step therapy provision was implemented, the step therapy patients incurred $99 more in healthcare costs per quarter, on average, than the comparison group.

"Under step therapy, patients who are newly prescribed a second-line medication may be denied coverage -- unless their doctor obtains prior approval from the health plan or changes the prescription to a first-line drug," said Tami L. Mark, the study's lead author and a research director in the Healthcare business of Thomson Reuters. "Patients who are unwilling to switch or unable to overcome administrative hurdles may go without medication. That may cause their medical condition to deteriorate and increase their need for medical interventions in the future.

"If that happens, it can wipe out savings derived from step therapy," Mark said. "Further research is needed to understand why these unintended consequences may happen and how they might be avoided."

The study, sponsored by Pfizer, Inc., was published in the February issue of The American Journal of Managed Care. Researchers analyzed insurance claims for 11,851 people with employer-sponsored health coverage that incorporated a step therapy protocol for antihypertensive drugs. Their use of healthcare services was compared with a group of 30,882 antihypertensive drug users who did not participate in a step therapy program.

About Thomson Reuters

The Healthcare business of Thomson Reuters produces insights, information, benchmarks and analysis that enable organizations to manage costs, improve performance and enhance the quality of healthcare. Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. Thomson Reuters shares are listed on the New York Stock Exchange (NYSE: TRI); Toronto Stock Exchange (TSX: TRI); London Stock Exchange (LSE: TRIL); and Nasdaq (Nasdaq: TRIN). For more information, go to www.thomsonreuters.com.


'/>"/>
SOURCE Thomson Reuters
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Thomson Reuters Announces 100 Top Hospitals Award Winners
2. Shands HealthCare Selects Micromedex CareNotes System from Thomson Reuters to Improve Patient Education
3. Thomson Reuters Publishes Pharma Matters White Paper, The Five Myths of Generic Competition
4. Thomson Reuters Study Tracks Impact of Recession on Hospitals
5. VHA Selects Clinical Xpert from Thomson Reuters as its Preferred Solution for Mobile Clinical Improvement Systems
6. Molecular Oncology accepted into Thomson Reuters index
7. Thomson Reuters Releases 2009 Patent Focus Report
8. Kids and Their Families Are Hit Hardest During Flu Season, According to Thomson Reuters Study
9. Thomson Reuters Launches Liquent PublishPerfect(TM)
10. CMS Selects Thomson Reuters to Help Implement Medicare Medical Home Demonstration Project for Medicare Recipients
11. Thomson Reuters Installs Clinical Xpert at Catholic Healthcare West for HIS Downtime Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 23, 2017 , ... The January 2017 issue of the ... study on how outdoor behavioral healthcare (OBH) – also known as wilderness therapy – ... while experiencing an increased sense of purpose both during and after treatment. , ...
(Date:1/24/2017)... ... January 23, 2017 , ... ... a new plugin that allows sleep centers to automatically connect and initialize all ... a thin client browser plugin is quickly installed on first use and then ...
(Date:1/23/2017)... Alto, CA (PRWEB) , ... ... ... a provider of translation and localization services for life science companies, has ... and inspection organization, TÜV SÜD America. ISO 17100 is the globally recognized ...
(Date:1/23/2017)... ... 23, 2017 , ... Wooden and plastic balance boards have been around since at least the ... Board is the first and only balance board to use a patent-pending design featuring ... at the same time as well as skill-level adjustable for all ages and abilities. ...
(Date:1/23/2017)... Indiana (PRWEB) , ... January 23, 2017 , ... ... Center for Assisted Living (IHCA/INCAL), will serve as a healthcare industry expert at ... 23. The panel discussion, moderated by Inside Indiana Business host Gerry Dick, will ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... Stock-Callers.com today presents the following Generic ... CPRX ), Sophiris Bio Inc. (NASDAQ: SPHS ), ... Therapeutics Inc. (NASDAQ: AGRX ). These companies are ... late trade on Friday, January 20 th , 2017, with ... of health care companies in the S&P 500 also were ...
(Date:1/23/2017)... , January 23, 2017 The global  anxiety disorders and ... by 2025. The rising incidence of depression worldwide is anticipated to drive the ... resulted in the declining demand for antidepressants in the recent years. ... ... Grand View Research Logo ...
(Date:1/23/2017)... DIEGO and PALMA, Spain ... Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company ... that the first patient has been enrolled in ... lead candidate, SNF472, for the treatment of cardiovascular ... (HD). Most ESRD patients, in the ...
Breaking Medicine Technology: